The invention provides for a vaccine against S. suis serotype 2. The vaccine comprises chemically synthesized fragments and thus may be made widely commercially available. The vaccine is used in the livestock production and may be adapted for use against other serotypes of S. suis such as serotypes 1, 1/2, 3, 9, and 14. Also, the vaccine may be adapted for use in humans.
Provided herein are biopanning methods for identifying peptides that bind to one or more glial cell subtypes, and peptides identified using the methods described herein. In some embodiments, provided herein are biopanning methods for identifying peptides that bind to glial cell subtypes including surveying glial cells, active glial cells, and/or primed glial cells.
The present invention relates to a lipid emulsion for total parenteral and enteral (oral or through gastric or duodenal tubes) nutrition. The lipid emulsion has advantageous immuno-modulating, anti-inflammatory, and anti-diabetic effects. The lipid emulsion may also comprise a pharmaceutical drug, can be used as a detoxifier, or for reversing negative effects from ischemia-reperfusion injury.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 43/00 - Drugs for specific purposes, not provided for in groups
4.
PROCESS FOR THE SELECTIVE CATALYTIC HYDROGENATION OF DIENONES
The present disclosure provides a catalyst system that is capable of selectively hydrogenating (2,3)/(4,5) and (2,3)/(5,6) dienones with hydrogen gas. Specifically, the present disclosure provides catalysts capable of providing high selectivity for the reduction even in the absence of catalyst poisons such as pyridine, pyrazine, quinoline, and quinoxaline
C07C 45/62 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by hydrogenation of carbon-to-carbon double or triple bonds
C07C 49/203 - Unsaturated compounds containing keto groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
C07C 49/21 - Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing rings other than six-membered aromatic rings
C07C 67/303 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenation of unsaturated carbon-to-carbon bonds
C07C 69/533 - Monocarboxylic acid esters having only one carbon-to-carbon double bond
5.
SYNTHETIC GLYCOCONJUGATE VACCINE PROTOTYPE AGAINST STREPTOCOCCUS SUIS
The invention provides for a vaccine against S. suis serotype 2. The vaccine comprises chemically synthesized fragments and thus may be made widely commercially available. The vaccine is used in the livestock production and may be adapted for use against other serotypes of S. suis such as serotypes 1, 1/2, 3, 9, and 14. Also, the vaccine may be adapted for use in humans.
A device for detecting environmental contaminants, diseases, and acute medical conditions related to heart failure identifies pathogens or troponins before infection or damage to heart muscles using an ultrasensitive high Q-factor AT-cut quartz crystal microbalance (QCM) that can measure from a single pg to a single fg. The device has a set of five disks of a QCM with a 10 mm diameter and a full coated bottom electrode, with an upper electrode with a center dot with different diameters labelled as 1 mm, 2 mm, 3 mm, 4 mm, and 5 mm. The full coating denoting an electrically continuous thickness of at last one monolayer. Measured parameters from the five disks include Q-factors, impedance, dissipation factors (D) and frequency shift (Δf). Q-factors are used to calculate the Allman deviation σ(τ) and measured frequencies are converted to mass sensitivity using the Sauerbrey mass sensitivity coefficient (K).
G01N 29/036 - Analysing fluids by measuring frequency or resonance of acoustic waves
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
G01N 29/22 - Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic wavesVisualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object Details
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
The United States of America, as represented by the Secretary of the Navy (USA)
University of Alberta (Canada)
Inventor
Johnson, Mark B
Elezzabi, Abdulhakem
Chau, Kenneth J.
Abstract
A photonic/plasmonic device is disclosed that uses a ferroelectric material and its magnetization state in order to affect the physical properties of electromagnetic waves. The magnetization state of the ferromagnetic material may either be zero or nonzero. When the magnetization state of the ferromagnetic material is non-zero physical properties of the electromagnetic waves are altered. This effect can be used to make switches and the like.
G02F 1/09 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on magneto-optical elements, e.g. exhibiting Faraday effect
9.
METHODS, APPARATUS, AND SENSORS FOR TRACING FRAC FLUIDS IN MINERAL FORMATIONS, PRODUCTION WATERS, AND THE ENVIRONMENT USING MAGNETIC PARTICLES
In some embodiments, the present invention pertains to methods of detecting a contamination of an environment by a fracture fluid that comprises magnetic particles. In some embodiments, such methods include: (1) collecting a sample from the environment; and (2) measuring a magnetic susceptibility of the sample in order to detect the presence or absence of the magnetic particles. Further embodiments of the present invention pertain to methods of tracing fracture fluids in a mineral formation. In some embodiments, such methods include: (1) associating the fracture fluids with magnetic particles; (2) introducing the fracture fluids into the mineral formation; and (3) measuring a magnetic susceptibility of the fracture fluids. Additional embodiments of the present invention pertain to fracture fluids containing the aforementioned magnetic particles, the actual magnetic particles, and methods of making said magnetic particles.
A parameter of a reservoir, such as an oil, gas, or water reservoir, is determined by measuring a magnetic susceptibility of magnetic particles added to the reservoir, and then correlating the measured magnetic susceptibility to at least one value associated with a parameter of the reservoir. The correlating process compares predetermined parameter information that is a function of magnetic susceptibility to the measured magnetic susceptibility to determine at least one value that is associated with the at least one parameter of the reservoir. The reservoir parameters may include fluid permeability, permeability anisotropy, fracture location, and fracture anisotropy. In some embodiments, the magnetic particles contain manganese or zinc doped iron-oxide particles.
G01V 3/40 - Electric or magnetic prospecting or detectingMeasuring magnetic field characteristics of the earth, e.g. declination or deviation specially adapted for measuring magnetic field characteristics of the earth
The present invention is directed to implants and the modification of the surface of implants using amino acid or polypeptide functionalized rosette nanotubes.
C07K 5/11 - Tetrapeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
C07K 5/09 - Tripeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
Materials and methods involved in assessing tissue fibrosis and atrophy in mammals. For example, materials and methods involved in detecting organ (e.g., kidney) fibrosis/atrophy due to organ rejection are provided, as are materials and methods for determining the extent of fibrosis/atrophy in mammals such as humans, for example.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
13.
Method of systematic construction of space-time constellations, system and method of transmitting space-time constellations
Space-time code, and methods for constructing space-time codes are provided. The space-time coder performs a respective linear transformation on each of P sets of K modulated symbols of a modulated symbol stream to produce P sets of T linearly transformed symbols, applies a respective phase rotation to each set of T linearly transformed symbols to produce a respective set of T phase rotated symbols, and performs a threading operation on the sets of T phase rotated symbols to produce P threaded sequences that define M output sequences. During each of T symbol periods, a respective one of the P threaded sequences includes a symbol from one of the P sets of phase rotated symbols. At least one symbol from each set of phase rotated symbols appears in each output sequence, where M>=2, 2<=P<=M, and T>=M and M>=K.
H04N 7/12 - Systems in which the television signal is transmitted via one channel or a plurality of parallel channels, the bandwidth of each channel being less than the bandwidth of the television signal
14.
Method of systematic construction of space-time constellations, system and method of transmitting space-time constellations
Space-time code, and methods for constructing space-time codes are provided. The space-time coder performs a respective linear transformation on each of P sets of K modulated symbols of a modulated symbol stream to produce P sets of T linearly transformed symbols, applies a respective phase rotation to each set of T linearly transformed symbols to produce a respective set of T phase rotated symbols, and performs a threading operation on the sets of T phase rotated symbols to produce P threaded sequences that define M output sequences; the threading operation being such that each threaded sequence is an allocation of output sequences over time of a respective one of the P sets of T phase rotated symbols in which all of the output sequences are used by each threaded sequence; during each of T symbol periods, a respective one of the P threaded sequences includes a symbol from one of the P sets of phase rotated symbols; and at least one symbol from each set of phase rotated symbols appears in each output sequence; where M>=2, 2<=P<=M, and T>=M and M>=K.
H04B 7/02 - Diversity systemsMulti-antenna systems, i.e. transmission or reception using multiple antennas
15.
Associations of polymorphisms in the fibroblast growth factor 8 (FGF8) and its haplotypes with carcass quality, growth and feed efficiency in beef cattle
The physiological regulation of intake, growth and energy partitioning in animals is under the control of multiple genes, which may be important candidates for unraveling the genetic variation in economically relevant traits in beef production. The present invention relates to the identification of single nucleotide polymorphisms (SNPs) within the bovine gene encoding fibroblast growth factor 8 (“FGF8”) and their associations with economically relevant traits in beef production. The invention further encompasses methods and systems, including network-based processes, to manage the SNP data and other data relating to specific animals and herds of animals, veterinarian care, diagnostic and quality control data and management of livestock which, based on genotyping, have predictable meat quality traits, husbandry conditions, animal welfare, food safety information, audit of existing processes and data from field locations.
An effective non-intrusive data-based monitoring method may reduce the cost of control loop performance maintenance by screening and short-listing those control loops or valves that need maintenance. The invention comprises a data-based, model-free, non-invasive method that can automatically detect and quantify stiction present in control valves. The method does not require the implementation of any additional valve travel test or, as commonly known, bump test of the control loop. The method may detect and quantify stiction using controlled variable (pv), controller output (op) and set point (sp) data. It does not require valve positioner (mv) data.
G05B 13/02 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric
Compounds comprising a saccharide molecule and a 5-deoxy-5-methylthio-xylofuranose (MTX) moiety or a 5-deoxy-5-methylsulfoxy-xylofuranose (MSX) moiety, and use of such compounds in methods for modulating inflammation and immune responses.
A61P 31/06 - Antibacterial agents for tuberculosis
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
C07H 5/10 - Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium, or tellurium to sulfur
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (USA)
UNIVERSITY OF ALBERTA (Canada)
Inventor
Hodges, Robert S.
Irvin, Randall T.
Giltner, Carmen
Van Schaik, Erin
Abstract
The present invention relates to a composition and method for preventing or inhibiting biofilm formation on biotic or abiotic surfaces. The composition comprises a peptide based on the C-terminal receptor binding domain of Pseudomonas aeruginosa type IV pilin, which binds to an abiotic surface (e.g., steel, plastic) with high affinity and prevents binding of a variety of P. aeruginosa strains to the surface. The inventive composition represents a non-toxic inhibitor for biofilm formation, particularly on an abiotic surface, which is responsible for a large number of problematic diseases and massive economic losses. The inventive method is useful as a safe and environmentally friendly means of modifying a surface of a variety of biomedical, nanotechnological, and biotechnological devices or articles.
The present invention is related to the discovery that serpina3n, a secreted protein, binds to and inhibits granzyme B activity. The invention thus provides cells that include a polynucleotide encoding a granzyme B inhibitory serpin, pharmaceutical compositions including a granzyme B inhibitory serpin or a polynucleotide encoding a granzyme B inhibitory serpin, methods for treating a patient in need of immunosuppression by administration of a granzyme B inhibitory serpin, and methods of transplanting cells (e.g., islet cells) expressing a granzyme B inhibitory serpin.
This document relates to methods and materials involved in detecting tissue rejection (e.g., organ rejection). For example, this document relates to methods and materials involved in the early detection of kidney tissue rejection.
The invention provides novel compounds of the Formula (I) that stimulate rates of glucose oxidation in myocardial cells: Formula (I) wherein W, Cyc, p, Y, X, Z, R, R1, R2, R3, R4, I, m and n are as defined for Formula (I) herein. The invention also relates to pharmaceutical compositions comprising compounds capable of stimulation of glucose oxidation, methods for increasing glucose oxidation rates in myocardial cells, and methods of treatment of myocardial ischemia.
C07C 69/74 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
A61K 31/21 - Esters, e.g. nitroglycerine, selenocyanates
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
C07C 321/22 - Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of rings other than six-membered aromatic rings
C07C 323/51 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
C07C 327/24 - Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
C07D 307/54 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
